

Published in final edited form as:

Nat Genet. 2013 December ; 45(12): 1452–1458. doi:10.1038/ng.2802.

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease

A full list of authors and affiliations appears at the end of the article.

Abstract

Eleven susceptibility loci for late-onset Alzheimer’s disease (LOAD) were identified by previous studies; however, a large portion of the genetic risk for this disease remains unexplained. We conducted a large, two-stage meta-analysis of genome-wide association studies (GWAS) in individuals of European ancestry. In stage 1, we used genotyped and imputed data (7,055,881 SNPs) to perform meta-analysis on 4 previously published GWAS data sets consisting of 17,008 Alzheimer’s disease cases and 37,154 controls. In stage 2, 11,632 SNPs were genotyped and tested for association in an independent set of 8,572 Alzheimer’s disease cases and 11,312 controls. In addition to the *APOE* locus (encoding apolipoprotein E), 19 loci reached genome-wide significance ($P < 5 \times 10^{-8}$) in the combined stage 1 and stage 2 analysis, of which 11 are newly associated with Alzheimer’s disease.

Alzheimer’s disease is a devastating neurological disorder primarily affecting the elderly. The disease manifests with progressive deterioration in cognitive functions, leading to loss of autonomy. The *APOE* gene (encoding apolipoprotein E) is a major genetic risk factor for Alzheimer’s disease^{1,2}. Previous GWAS in individuals of European ancestry identified nine

Correspondence should be addressed to P.A. (philippe.amouyel@pasteur-lille.fr) or J.W. (williamsj@cardiff.ac.uk).

⁸⁷Full lists of members and affiliations appear in the Supplementary Note.

¹⁴⁵These authors contributed equally to this work.

¹⁴⁶These authors jointly directed this work.

Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

AUTHOR CONTRIBUTIONS

Study concept and design: J.-C.L., C.A.I.-V., D. Harold, A.C.N., A.L.D., J.C.B., A.V.S., M.A.I., H. Schmidt, A.L.F., V.G., O.L.L., D.W.T., D. Blacker, T.H.M., T.B.H., J.I.R., W.A.K., M. Boada, R. Schmidt, R.M., A.H., B.M.P., J.L.H., P.A.H., M.L., M.A.P.-V., L.J.L., L.A.F., C.M.v.D., V.M., S. Seshadri, J.W., G.D.S. and P.A. **Acquisition of data:** J.-C.L., C.A.I.-V., D. Harold, C. Bellenguez, R. Sims, G.J., B.G.-B., G.R., N.J., V.C., C. Thomas, D.Z., Y.K., A.G., H. Schmidt, M.L.D., M.-T.B., S.-H.C., P.H., V.G., C. Baldwin, C.C., C. Berr, O.L.L., P.L.D.J., D.E., L. Letenneur, G.E., K.S., A.M.G., N.F., M.J.H., M.I.K., E.B.L., A.J.M., C.D., S.T., S. Love, E.R., P.S.G.-H., L.Y., M.M.C., D. Beekly, F.Z., O.V., S.G.Y., W.G., M.J.O., K.M.F., P.V.J., M.C.O., L.B.C., D.A.B., T.B.H., R.F.A.G.d.B., T.J.M., J.I.R., K.M., T.M.F., W.A.K., J.F.P., M.A.N., K.R., J.S.K.K., E.B., M.R., M. Boada, L.-S.W., J.-F.D., C. Tzourio, M.M.N., B.M.P., L.J., J.L.H., M.L., L.J.L., L.A.F., A.H., C.M.v.D., S. Seshadri, J.W., G.D.S. and P.A. **Sample contribution:** A. Ruiz, F. Pasquier, A. Ramirez, O.H., J.D.B., D. Campion, P.K.C., C. Baldwin, T.B., C.C., D. Craig, V.D., J.A.J., S. Lovestone, F.J.M., D.C.R., K.S., A.M.G., N.F., M.G., K. Brown, M.I.K., L.K., P.B.-G., B.M., R.G., A.J.M., D.W., E.R., J.G., P.S.G.-H., J.C., A.L., A. Bayer, M.T., P. Bossù, G.S., P. Proitsi, J.C., S. Sorbi, F.S.-G., N.C.F., J.H., M.C.D.N., P. Bosco, R.C., C. Brayne, D.G., M. Mancuso, F.M., S. Moebus, P.M., M.D.Z., W.M., H. Hampel, A.P., M. Bullido, F. Panza, P.C., B.N., M. Mayhaus, L. Lannfelt, H. Hakonarson, S.P., M.M.C., M.I., V.A., S.G.Y., E.C., C. Razquin, P. Pastor, I.M., O.C., H. Soininen, S. Mead, D.A.B., L.F., C.H., P. Passmore, T.J.M., K. Bettens, A. Brice, D. Hannequin, K.R., M.R., M.H., D.R., C.G. and C.V.B. **Data analysis:** C.A.I.-V., D. Harold, A.C.N., R. Sims, C. Bellenguez, G.J., A.L.D., J.C.B., G.W.B., B.G.-B., G.R., T.A.T.-W., N.J., A.V.S., V.C., M.A.I., D.Z., Y.K., B.N.V., C.-F.L., A.G., B.K., C. Reitz, J.R.G., O.V., W.A.K., K.L.L., K.L.H.-N., E.R.M., L.-S.W., B.M.P., M.L., V.M. and J.W. **Statistical analysis and interpretation:** J.-C.L., C.A.I.-V., D. Harold, A.C.N., C. Bellenguez, G.J., A.L.D., J.C.B., G.W.B., T.A.T.-W., A.V.S., V.C., M.A.I., B.N.V., Y.K., C.-F.L., B.K., C. Reitz, A.L.F., N.A., J.R.G., R.F.A.G.d.B., W.A.K., K.L.L., E.R.M., L.-S.W., B.M.P., L.J., J.L.H., P.A.H., M.A.P.-V., L.J.L., L.A.F., C.M.v.D., V.M., S. Seshadri, J.W., G.D.S. and P.A. **Drafting of the manuscript:** J.-C.L., C.A.I.-V., D. Harold, A.C.N., C. Bellenguez, A.L.D., J.C.B., A.V.S., R.M., B.M.P., J.L.H., M.A.P.-V., L.J.L., L.A.F., C.M.v.D., C.V.B., S. Seshadri, J.W., G.D.S. and P.A.

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

other genomic regions associated with LOAD^{3–7}. Recently, a rare susceptibility variant in *TREM2* was identified^{8,9}. The search for additional genetic risk factors requires large-scale meta-analysis of GWAS to increase statistical power. Under the banner of I-GAP (International Genomics of Alzheimer's Project), we conducted a meta-analysis of 4 GWAS samples of European ancestry totaling 17,008 cases and 37,154 controls (stage 1) followed up by genotyping of 11,632 SNPs showing moderate evidence of association ($P < 1 \times 10^{-3}$ in stage 1) in an independent sample that included 8,572 cases and 11,312 controls (stage 2).

In the stage 1 meta-analysis, we used data from four consortia: the Alzheimer's Disease Genetic Consortium (ADGC), the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the European Alzheimer's Disease Initiative (EADI) and the Genetic and Environmental Risk in Alzheimer's Disease (GERAD) Consortium (Table 1, Online Methods, Supplementary Table 1 and Supplementary Note). We used European population reference (EUR) haplotype data from the 1000 Genomes Project (2010 interim release based on sequence data freeze from 4 August 2010 and phased haplotypes from December 2010) to impute genotypes for up to 11,863,202 SNPs per data set. We excluded SNPs that did not pass quality control in each study (Supplementary Table 2 and Supplementary Note). Our meta-analysis included SNPs either genotyped or successfully imputed in at least 40% of the Alzheimer's disease cases and 40% of the control samples across all data sets (7,055,881 SNPs; Online Methods). In each data set, genotype dosages were analyzed as described in the Supplementary Note (Supplementary Table 2). We performed meta-analysis of the results after applying genomic control correction to each study. The genomic control inflation factor for the meta-analysis was 1.087 for the full set of SNPs and 1.082 after excluding SNPs within the *APOE* locus (chr. 19: 45,409,039–45,412,650) and within 500 kb of SNPs associated with Alzheimer's disease at a prespecified level of genome-wide significance ($P < 5 \times 10^{-8}$) in stage 1 (see Supplementary Fig. 1 for quantile-quantile plots).

In addition to the *APOE* locus, 14 genomic regions had associations that reached the genome-wide significance level (Fig. 1). Nine had been previously identified by GWAS as genetic susceptibility factors^{3–7}, and five (*HLA-DRB5–HLA-DRB1*, *PTK2B*, *SORL1*, *SLC24A4–RIN3* and *DSG2*) represent newly associated loci (Table 2). *SORL1* had previously been identified as an Alzheimer's disease gene through candidate gene approaches and in a GWAS combining ADGC and Asian samples¹⁰. Genes attributed to a signal were those closest to the most significantly associated SNP. However, we are aware that these are potentially not the causative genes. Detailed results for each region are given in Supplementary Figure 2–7.

In stage 2, we selected for genotyping all stage 1 SNPs with a P value less than 1×10^{-3} , excluding SNPs flanking *APOE* (chr. 19: 45,409,039–45,412,650) ($n = 19,532$; see URLs for database access). From the initial set of SNPs, 14,445 could be genotyped using Illumina iSelect technology. After quality control procedures (Online Methods), we considered 11,632 SNPs for association analysis. The stage 2 sample included 8,572 cases and 11,312 controls of European ancestry originating from Austria, Belgium, Finland, Germany, Greece, Hungary, Italy, Spain, Sweden, the UK and the United States (Table 1 and Supplementary Note). We observed 116 SNPs showing the same risk allele and direction of association in stages 1 and 2 that were significantly associated with Alzheimer's disease risk in stage 2 after a strict Bonferroni correction for multiple testing ($P < 4.3 \times 10^{-6}$). Of these 116 SNPs, 80 had been associated at genome-wide significance with Alzheimer's disease risk in stage 1. Additionally, in analyses in stage 2, 2,562 SNPs were associated with Alzheimer's disease at a nominal level of significance ($P < 0.05$), having the same risk allele and direction of association as in stage 1.

The results from stages 1 and 2 and from the combined stage 1 and stage 2 data sets, which represent a secondary discovery effort, are shown in Table 2. With the exception of *CD33* and *DSG2*, we nominally replicated all loci that surpassed the genome-wide significance level in stage 1. Inability to replicate *DSG2* is not surprising, as evidence of association for this locus was based on data for a single SNP and was not supported by data from surrounding SNPs in linkage disequilibrium (LD, $r^2 > 0.8$; Supplementary Fig. 7b). Moreover, seven new loci reached the genome-wide significance level in the combined analysis (Table 2). More detailed results for the seven newly identified LOAD loci are provided in Supplementary Figure 8–11. There was no significant heterogeneity across studies at any of the loci, except at *DSG2* (Table 2 and Supplementary Fig. 12–16). To identify potential causative genes, we also examined all SNPs with association $P < 5 \times 10^{-8}$ that were within 500 kb of the top SNP at each locus to identify *cis* expression quantitative trait locus (*cis*-eQTL) associations (Online Methods and Supplementary Table 3).

The results from the combined stage 1 and stage 2 data sets also identified 13 loci with suggestive evidence of association ($P < 1 \times 10^{-6}$) (Supplementary Table 4). Among these, we detected a signal for rs9381040 ($P = 6.3 \times 10^{-7}$), which is located approximately 5.5 kb away from the 3' end of *TREML2* and 24 kb away from the 5' end of *TREM2*. *TREM2* was recently reported to carry a rare variant (encoding p.Arg47His) associated with three- to fourfold increased risk of developing Alzheimer's disease^{8,9}. This region also reached genome-wide significance in a study of cerebral spinal fluid levels of phosphorylated tau, a biomarker for Alzheimer's disease¹¹.

Beyond the already known, GWAS-defined genes (*ABCA7*, *BINI*, *CD33*, *CLU*, *CRI*, *CD2AP*, *EPHA1*, *MS4A6A-MS4A4E* and *PICALM*), the most significant new association was in the *HLA-DRB5-DRB1* region (encoding major histocompatibility complex, class II, DR β 5 and DR β 1, respectively). This region is associated with immunocompetence and histocompatibility and, interestingly, with risk of both multiple sclerosis and Parkinson disease^{12,13}. Owing to the complex genetic organization of the human leukocyte antigen (HLA) region on chromosome 6, we were unable to define which gene(s) are responsible for this signal (Supplementary Fig. 6a).

The second strongest signal was within the *SORL1* gene (encoding sortilin-related receptor, L(DLR class) 1). Our data clearly demonstrated that this gene was associated at genome-wide significance in European samples. *SORL1* is noteworthy, as it is associated with increased risk of both autosomal dominant and sporadic forms of Alzheimer's disease^{14,15} and represents the first LOAD gene that directly connects aberrant trafficking and metabolism of the amyloid precursor protein (APP) to LOAD¹⁴.

The third locus, *PTK2B* (encoding protein tyrosine kinase 2 β), is only approximately 130 kb away from *CLU*, but we believe the two signals are independent because (i) the two most strongly associated SNPs within each of these two genes are not in LD ($D' = 0.06$ and $r^2 = 0.003$ as computed using 1000 Genomes Project data); (ii) a recombination peak exists between the two loci (Fig. 2); and (iii) conditional analysis in the stage 2 data confirmed the independence of the *PTK2B* association (Supplementary Fig. 17 and Supplementary Table 5). The protein encoded by *PTK2B* may be an intermediate between neuropeptide-activated receptors or neurotransmitters that increase calcium flux and the downstream signals regulating neuronal activity such as mitogen-activated protein kinase (MAPK) signaling¹⁶. *PTK2B* is involved in the induction of long-term potentiation in the hippocampal CA1 (cornu ammonis 1) region, a central process in the formation of memory¹⁷. We cannot, however, exclude the possibility that there are multiple signals in the *PTK2B-CLU* region that are functionally connected to a single gene. For instance, two SNPs associated with

genome-wide significance in the *PTK2B-CLU* region are eQTLs for the gene *DPYSL2* that has been implicated in Alzheimer's disease¹⁸ (Supplementary Table 3).

The fourth locus was *SLC24A4* (encoding solute carrier family 24 (sodium/potassium/calcium exchanger), member 4). The *SLC24A4* gene encodes a protein involved in iris development and hair and skin color variation in humans in addition to being associated with the risk of developing hypertension^{19,20}. *SLC24A4* is also expressed in the brain and may be involved in neural development²¹. Of note, in the vicinity of the most strongly associated SNP is another gene called *RIN3* (encoding Ras and Rab interactor 3), and its gene product directly interacts with the *BINI* gene product²², a protein that may be connected to tau-mediated pathology²³.

In addition to these four loci reaching genome-wide significance in stage 1, seven new loci reached genome-wide significance in the combined analysis.

The strongest association at one of these new loci was intronic in the *ZCWPWI* gene (encoding zinc finger, CW type with PWWP domain 1), whose corresponding protein modulates epigenetic regulation²⁴. However, the region defined by all the SNPs associated with Alzheimer's disease risk in our data is large and contains about ten genes (Supplementary Fig. 9b). Another interesting possible candidate gene in the *ZCWPWI* region is *NYAPI*, as disruption of the corresponding gene in mice affects brain size, neurite elongation and, more generally, neuronal morphogenesis²⁵. Our data do not resolve which gene in this region may be causal.

A second locus was within the *CELF1* gene (encoding CUGBP, Elav-like family member 1), whose gene product is a member of the protein family that regulates pre-mRNA alternative splicing²⁶. As with the *ZCWPWI* locus, the region of interest is large and contains about ten genes (Supplementary Fig. 10a). Among these genes is *MADD* (encoding MAP kinase-activating death domain), the reduced expression of which may affect long-term neuronal viability in Alzheimer's disease²⁷.

A discrete signal was observed adjacent to *NME8* (encoding NME/ NM23 family member 8), which is responsible for primary ciliary dyskinesia type 6 (ref. 28).

The *FERMT2* gene (encoding fermitin family member 2) is expressed in the brain. Its corresponding protein localizes to cell matrix adhesion structures, activates integrins, is involved in the orchestration of actin assembly and cell shape modulation, and is an important mediator of angiogenesis²⁹. An association between the *Drosophila melanogaster* ortholog of *FERMT2* (*fit1/fit2*) and tau-mediated toxicity was recently described³⁰.

We identified a fifth signal on chromosome 20 at *CASS4* (encoding Cas scaffolding protein family member 4). Little is known about the function of the encoded protein. However, the *Drosophila* CASS family ortholog (*p130CAS*) binds to CMS, the *Drosophila* ortholog of *CD2AP* (CMS), a known Alzheimer's disease susceptibility gene (Table 2) that is involved in actin dynamics³¹.

Another locus was identified at *INPP5D* (encoding inositol polyphosphate-5-phosphatase, 145 kDa) on chromosome 2. *INPP5D* is expressed at low levels in the brain, but the encoded protein has been shown to interact with *CD2AP*, whose corresponding gene is one of the Alzheimer's disease genes previously identified by GWAS³², and to modulate, along with *GRB2*, metabolism of *APP*³³.

We identified a seventh signal adjacent to *MEF2C* (encoding myocyte enhancer factor 2). Mutations at this locus are associated with severe mental retardation, stereotypic

movements, epilepsy and cerebral malformation³⁴. The MEF2C protein limits excessive synapse formation during activity-dependent refinement of synaptic connectivity and thus may facilitate hippocampal-dependent learning and memory³⁵.

In summary, our Alzheimer's disease GWAS meta-analysis has identified 11 new susceptibility loci in addition to the already known *ABCA7*, *APOE*, *BINI*, *CLU*, *CRI*, *CD2AP*, *EPHA1*, *MS4A6A-MS4A4E* and *PICALM* genes. However, we were not able to replicate association of *CD33* in our stage 2 analysis ($P = 0.61$). We did not detect any biases in terms of imputation in our discovery data sets or genotyping in our replication data sets (data not shown), suggesting a potential statistical fluctuation across our populations as an explanation for the lack of replication. However, recent data suggest that genetically determined decreased *CD33* expression might reduce Alzheimer's disease risk and interfere with amyloid β peptide clearance³⁶, a dysfunction thought to be central in late-onset forms of Alzheimer's disease³⁷. Further investigations in independent case-control studies will thus be required to confirm or refute the association of *CD33* with Alzheimer's disease.

The newly associated loci reinforce the importance of some previously suspected pathways such as APP (*SORL1* and *CASS4*) and tau (*CASS4* and *FERMT2*) in pathology. Several candidate genes at these loci are involved in pathways already shown to be enriched for association signal in Alzheimer's disease GWAS^{38,39}, such as immune response and inflammation (*HLA-DRB5-DRB1*, *INPP5D* and *MEF2C*), which is also supported by the described association of Alzheimer's disease with *CRI* (ref. 3) and *TREM2* (refs. 8,9), cell migration (*PTK2B*) and lipid transport and endocytosis (*SORL1*). Our results also suggest the existence of new pathways underlying Alzheimer's disease. These pathways could include hippocampal synaptic function (*MEF2C* and *PTK2B*), cytoskeletal function and axonal transport (*CELFI*, *NME8* and *CASS4*), regulation of gene expression and post-translational modification of proteins, and microglial and myeloid cell function (*INPP5D*).

Examining the genetic effect attributable to all the associated loci, we demonstrated that the most strongly associated SNPs at each locus other than *APOE* had population-attributable fractions (PAFs) or preventive fractions between 1.0–8.0% in the stage 2 sample (Supplementary Table 6). Strong efforts in sequencing and post-GWAS analyses will now be required to fully characterize the candidate genes and functional variants responsible for the association of these GWAS-identified loci with Alzheimer's disease risk and to understand their exact roles in the pathophysiology of Alzheimer's disease^{40,41}.

URLs. Database access, http://www.pasteur-lille.fr/en/recherche/u744/Igap_stage1.zip; IMPUTE2, http://mathgen.stats.ox.ac.uk/impute/impute_v2.html; MaCH, <http://www.sph.umich.edu/csg/abecasis/MACH/>; ProbABEL, <http://www.genabel.org/packages/ProbABEL/>; SMARTPCA, <http://www.hsph.harvard.edu/alkes-price/software/>; GWAMA, <http://www.well.ox.ac.uk/gwama/>; LocusZoom, <http://csg.sph.umich.edu/locuszoom/>; PLINK, <http://pngu.mgh.harvard.edu/~purcell/plink/>; SNPTEST, https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html; Aberrant, <http://www.well.ox.ac.uk/software/>; Metal, <http://www.sph.umich.edu/csg/abecasis/metal/>; R, <http://www.r-project.org/>; R meta, <http://cran.r-project.org/web/packages/rmeta/index.html>; eQTL analyses (accessed 18 February 2013), <http://eqtl.uchicago.edu/cgi-bin/gbrowse/eqtl>.

ONLINE METHODS

All case-control studies are described in Table 1, in the Supplementary Note (see full description of the I-GAP data sets) and in Supplementary Tables 1, 7 and 8. Written informed consent was obtained from study participants or, for those with substantial cognitive impairment, from a caregiver, legal guardian or other proxy, and the study

protocols for all populations were reviewed and approved by the appropriate institutional review boards.

Imputation and SNP selection for stage 1 analysis

After quality control criteria were finalized for each individual and each sample collection (SNPs with call rates of <95% were excluded; Supplementary Note), IMPUTE2 (ref. 42) or MaCH/Minimac⁴³ software (Supplementary Table 2) was used to impute the genotypes of all participants with haplotypes derived from samples of European ancestry in the 1000 Genome Project (2010 interim release based on the sequence data freeze from 4 August 2010 and phased haplotypes from December 2010). In each data set, SNPs with R^2 or info score quality estimates of less than 0.3, as indicated by MaCH or IMPUTE2, respectively (with these two quality estimates described to be equivalent), were excluded from analyses. Similarly, SNPs with a MAF of <1% were also excluded. After these procedures, a maximum of 8,133,148 SNPs were retained that were present in at least 1 data set.

In each case-control data set, the association of LOAD with genotype dosage was analyzed by a logistic regression model including covariates for age, sex and principal components to adjust for possible population stratification (Supplementary Table 2). For the three CHARGE cohorts with incident Alzheimer's disease data, Cox proportional hazards models were used. The four consortia used different but analogous software for these analyses (PLINK⁴⁴, SNPTEST⁴⁵, ProbABEL⁴⁶ or R; Supplementary Table 2). Three of these tools were applied to the EADI data set for quality control, and very similar results were observed. After the exclusion of SNPs showing logistic regression coefficient $|\beta| > 5$ or P value equal to 0 or 1, the maximum number of SNPs in any data set was 8,131,643. Each consortium uploaded summarized results for each SNP to an internal I-GAP website for access by members of each consortium.

SNPs genotyped or imputed in at least 40% of Alzheimer's disease cases and 40% of control samples were included in the meta-analysis. This threshold represented the best compromise between maximizing the total number of SNPs and maximizing the number of samples in which the given SNP was present. Indeed, analyzing all SNPs available in at least one study could have greatly increased the risk of false positives. On the other hand, studying SNPs only present in all studies could have led to the removal of SNPs of potential interest, even if those SNPs could have reached adequate statistical power in a more limited number of data sets (false negatives). This approach allowed us to increase homogeneity between studies for some SNPs by excluding poor quality data present only in a limited number of data sets of small size. This last selection step led to a final number of 7,055,881 SNPs in stage 1 analysis.

iSelect microarray design and stage 2 SNP quality control

SNPs associated with Alzheimer's disease risk and exhibiting P value $< 1 \times 10^{-3}$ in stage 1 analysis were selected for replication. A list of 19,532 SNPs was submitted to a devoted Illumina website to develop an iSelect microarray. A total of 16,732 SNPs exhibiting an Illumina score superior or equal to 0.4 were selected for microarray production. During the Illumina production process, 2,287 SNPs failed oligonucleotide synthesis, leading to a final number of 14,445 SNPs for which genotyping was attempted. Genotyping failure led to the further exclusion of an additional 1,999 SNPs as a result of the SNPs (i) having no intensity signal ($n = 559$), (ii) not being polymorphic ($n = 1,176$), (iii) only being found in a heterozygous state ($n = 248$) or (iv) having mismatched alleles compared to 1000 Genomes Project data ($n = 16$). Finally, several quality control measures were applied to the remaining 12,446 SNPs to detect potential biases in genotyping. We first tested for discrepancies in allelic frequency between the 1000 Genomes Project EUR reference panel and stage 2 data.

Allele frequencies for stage 2 data were estimated on 10,750 controls (see “Stage 2 sample quality control”) and after exclusion of Finnish individuals. The allelic test was performed with PLINK, and P values were computed by performing 4,500,000 permutations to avoid an assumption of Hardy-Weinberg equilibrium. In total, 798 SNPs showed a highly significant difference in terms of allele frequency between the 1000 Genomes Project EUR reference panel and stage 2 data ($P < 1 \times 10^{-5}$; Supplementary Fig. 18) and were excluded from the analysis.

Other SNP quality control steps were performed separately in data for each country. A SNP was considered of low genotyping quality in a country data set if it had missing genotype data for more than 10% of the individuals, if the P value for the Hardy-Weinberg test in controls was lower than 1×10^{-6} or if the P value for the test for differences in missingness between cases and controls was lower than 1×10^{-6} (see Supplementary Table 9 for differences in missingness assessed for suggestive and significant hits across European populations). These quality control steps led to the removal of 16 SNPs with low genotyping quality in data from all countries.

After SNP quality control, 11,632 SNPs were considered to be of high genotyping quality in at least 1 country and were analyzed in stage 2. For imputed data sets, SNPs were considered to be of low imputation quality if their info score was <0.3 .

Of note, of the 7,086 SNPs that we were unable to successfully genotype, only 471 were not tagged by another successfully genotyped variant (± 100 kb) and associated with a P value at least 10 times higher than that of the missing SNP. Because the vast majority of the untagged SNPs exhibited stage 1 P values between 1×10^{-3} and 1×10^{-4} (92%), the likelihood of missing a true association was considered to be low.

Stage 2 sample quality control

The iSelect microarray contained 33,368 SNPs, of which 11,632 were devoted to stage 2. These supplementary SNPs included various genetic data that allowed us to further refine our quality control processes. On the basis of data for all of these SNPs, we excluded individuals who had more than 3% missing genotypes, showed a discrepancy between reported sex and sex estimated on the basis of genetic data (genetic sex) or showed evidence of non-European ancestry. Duplicated and related individuals were identified (Supplementary Table 10). Briefly, discrepancies in sex were examined using genetic sex as estimated by PLINK on 40 SNPs on chromosome X. We also removed 93 individuals from a single plate for whom an abnormal number of discrepancies in sex were observed, suggesting that sample mixing had occurred. Using a panel of 261 ancestry-informative markers (AIMs), we performed a principal-component analysis (PCA) on HapMap 2 data with the function SMARTPCA from EIGENSOFT 4.2 software⁴⁷. For each country, individuals were projected onto the first two PCA axes to define their genetic ancestry. Individuals with evidence of non-European ancestry were then identified by applying a Bayesian clustering approach⁴⁸ to their coordinates on the first two axes. Identity by descent (IBD) was computed for all pairs of individuals using PLINK, and individuals in a pair with IBD greater than 0.98 were considered to be duplicates. If clinical data for duplicated individuals were discordant, both individuals were excluded. Otherwise, the individual with the greater proportion of missing genotype was excluded. Similarly, IBD was computed for all pairs of individuals in data from each country separately, using 6,764 autosomal SNPs with MAF of $>1\%$ and selected to minimize LD. Individuals in pairs with IBD greater than 0.2 were considered to be related and were iteratively removed so as to obtain a sample of unrelated individuals within each country data set.

Finally, individuals with missing clinical data and controls less than 25 years of age were excluded from the analysis. After sample quality control (Supplementary Table 10), 19,884 individuals (8,572 cases and 11,312 controls) were available for analysis in stage 2.

Statistical analysis

For the stage 1 meta-analysis, we undertook fixed-effects inverse variance-weighted meta-analysis with the standard errors of the β -coefficient scaled by the square roots of study-specific genomic inflation factors estimated before combining the summary statistics across data sets. Each consortium performed an independent stage 1 meta-analysis after downloading the data files available on the I-GAP website. Two software packages were used for meta-analysis: METAL⁴⁹ and GWAMA⁵⁰. Very similar results were generated independently of the software used and as expected, perfect matching was observed between the analyses undertaken by each of the 4 consortia.

For stage 2, association tests were performed for each country for all high-quality genotyped SNPs under an additive model, using logistic regression as implemented in PLINK. Analysis was adjusted for age, sex and principal components, when necessary. Using SMARTPCA, PCA was performed on individuals from each country separately. Difference in PCA coordinates between cases and controls were tested for the first four principal components, and analysis was further adjusted on principal components if the P value of this test was lower than 0.05. PCA for Bonn stage 2 samples was based on GWAS data. For imputed data sets, association tests were performed using likelihood score tests for missing data as implemented in SNPTEST. Genotyped and imputed German samples were analyzed separately, and results were then combined by fixed-effects meta-analysis using the inverse variance approach as implemented in METAL. Using this approach, a fixed-effects meta-analysis was then performed to combine stage 2 results from the different countries. We also performed the analysis separately for each center in stage 2 and combined the results by fixed-effects meta-analysis. Results were similar to those obtained when analysis was performed by country (data not shown).

We finally generated fixed-effects inverse variance-weighted meta-analyses by combining summary statistics across ADGC, CHARGE, EADI, GERAD and stage 2 data by country. At this point, we performed Cochran's Q test for heterogeneity and generated I^2 estimates with METAL to evaluate the possible effect of study heterogeneity on the results.

A graphic representation of the association signal in the stage 1 data was generated with LocusZoom software⁵¹ for all the loci of interest reaching a genome-wide significant level after combined stage 1 and stage 2 analyses.

PAF was calculated using the Levin equation⁵².

Annotation of I-GAP top SNPs for eQTLs

To gain further biological insights, we explored reported associations between SNPs in the top I-GAP loci and gene expression. We first selected all SNPs that reached genome-wide significance (P value $< 5 \times 10^{-8}$) in the combined stage 1 and stage 2 analysis and were located in a 500-kb window upstream or downstream of the top SNP at each locus (Table 2). We then searched for published data on gene expression associated with each of these SNPs in the eQTL database from the Pritchard laboratory (see URLs). For each reported eQTL gene and each type of eQTL association as defined in this database, we then counted the number of reported eQTL SNPs and selected the one with the lowest P value.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Jean-Charles Lambert^{1,2,3,145}, Carla A Ibrahim-Verbaas^{4,5,145}, Denise Harold^{6,145}, Adam C Naj^{7,8,145}, Rebecca Sims⁶, Céline Bellenguez^{1,2,3}, Gyungah Jun^{9,10,11}, Anita L DeStefano¹¹, Joshua C Bis¹², Gary W Beecham^{13,14}, Benjamin Grenier-Boley^{1,2,3}, Giancarlo Russo¹⁵, Tricia A Thornton-Wells¹⁶, Nicola Jones⁶, Albert V Smith^{17,18}, Vincent Chouraki^{1,2,3}, Charlene Thomas⁶, M Arfan Ikram^{4,5,19,20}, Diana Zelenika²¹, Badri N Vardarajan⁹, Yoichiro Kamatani²², Chiao-Feng Lin²³, Amy Gerrish⁶, Helena Schmidt²⁴, Brian Kunkle¹³, Melanie L Dunstan⁶, Agustin Ruiz²⁵, Marie-Thérèse Bihoreau²¹, Seung-Hoan Choi¹¹, Christiane Reitz^{26,27}, Florence Pasquier^{2,28}, Paul Hollingworth⁶, Alfredo Ramirez^{29,30}, Olivier Hanon³¹, Annette L Fitzpatrick^{12,32,33}, Joseph D Buxbaum^{34,35,36}, Dominique Campion³⁷, Paul K Crane³⁸, Clinton Baldwin⁹, Tim Becker^{39,40}, Vilmundur Gudnason^{17,18}, Carlos Cruchaga^{41,42}, David Craig⁴³, Najaf Amin⁵, Claudine Berr⁴⁴, Oscar L Lopez⁴⁵, Philip L De Jager^{46,47}, Vincent Deramecourt^{2,28}, Janet A Johnston⁴³, Denis Evans⁴⁸, Simon Lovestone⁴⁹, Luc Letenneur⁵⁰, Francisco J Morón⁵¹, David C Rubinsztein⁵², Gudny Eiriksdottir¹⁸, Kristel Slegers^{53,54}, Alison M Goate^{41,42}, Nathalie Fiévet^{1,3}, Matthew J Huentelman⁵⁵, Michael Gill⁵⁶, Kristelle Brown⁵⁷, M Ilyas Kamboh^{58,59}, Lina Keller⁶⁰, Pascale Barberger-Gateau⁵⁰, Bernadette McGuinness⁴³, Eric B Larson^{38,61}, Robert Green⁶², Amanda J Myers⁶³, Carole Dufouil⁵⁰, Stephen Todd⁴³, David Wallon³⁷, Seth Love⁶⁴, Ekaterina Rogaeva⁶⁵, John Gallacher⁶⁶, Peter St George-Hyslop^{52,65,67}, Jordi Clarimon^{68,69}, Alberto Lleo^{68,69}, Anthony Bayer⁶⁶, Debby W Tsuang⁷⁰, Lei Yu⁷¹, Magda Tsolaki⁷², Paola Bossù⁷³, Gianfranco Spalletta⁷³, Petroula Proitsi⁴⁹, John Collinge⁷⁴, Sandro Sorbi^{75,76}, Florentino Sanchez-Garcia⁷⁷, Nick C Fox⁷⁸, John Hardy^{79,80}, Maria Candida Deniz Naranjo⁷⁷, Paolo Bosco⁸¹, Robert Clarke⁸², Carol Brayne⁸³, Daniela Galimberti⁸⁴, Michelangelo Mancuso⁸⁵, Fiona Matthews⁸⁶, European Alzheimer's disease Initiative (EADI)⁸⁷, Genetic and Environmental Risk in Alzheimer's Disease (GERAD)⁸⁷, Alzheimer's Disease Genetic Consortium (ADGC)⁸⁷, Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)⁸⁷, Susanne Moebus⁸⁸, Patrizia Mecocci⁸⁹, Maria Del Zompo⁹⁰, Wolfgang Maier^{29,39}, Harald Hampel^{91,92}, Alberto Pilotto⁹³, Maria Bullido^{94,95,96}, Francesco Panza⁹⁷, Paolo Caffarra^{98,99}, Benedetta Nacmias^{75,76}, John R Gilbert^{13,14}, Manuel Mayhaus¹⁰⁰, Lars Lannfelt¹⁰¹, Hakon Hakonarson¹⁰², Sabrina Pichler¹⁰⁰, Minerva M Carrasquillo¹⁰³, Martin Ingelsson¹⁰¹, Duane Beekly¹⁰⁴, Victoria Alvarez¹⁰⁵, Fanggeng Zou¹⁰³, Otto Valladares²³, Steven G Younkin¹⁰³, Eliecer Coto¹⁰⁵, Kara L Hamilton-Nelson¹³, Wei Gu¹⁰⁰, Cristina Razquin¹⁰⁶, Pau Pastor^{106,107}, Ignacio Mateo^{108,109}, Michael J Owen⁶, Kelley M Faber¹¹⁰, Palmi V Jonsson^{17,111}, Onofre Combarros^{108,109}, Michael C O'Donovan⁶, Laura B Cantwell²³, Hilka Soininen^{112,113}, Deborah Blacker^{114,115}, Simon Mead⁷⁴, Thomas H Mosley Jr¹¹⁶, David A Bennett^{71,117}, Tamara B Harris¹², Laura Fratiglioni^{60,118}, Clive Holmes¹¹⁹, Renee F A G de Bruijn^{4,5,20}, Peter Passmore⁴³, Thomas J Montine¹²⁰, Karolien Bettens^{53,54}, Jerome I Rotter¹²¹, Alexis Brice^{122,123}, Kevin Morgan⁵⁷, Tatiana M Foroud¹¹⁰, Walter A Kukull³², Didier Hannequin³⁷, John F Powell⁴⁹, Michael A Nalls¹²⁴, Karen Ritchie^{44,125}, Kathryn L Lunetta¹¹, John S K Kauwe¹²⁶, Eric Boerwinkle^{127,128,129}, Matthias Riemenschneider¹⁰⁰, Mercè Boada^{25,130}, Mikko Hiltunen^{112,113}, Eden R Martin^{13,14}, Reinhold Schmidt¹³¹, Dan Rujescu¹³², Li-san Wang²³, Jean-François Dartigues^{50,133}, Richard Mayeux^{26,27}, Christophe Tzourio¹³⁴, Albert Hofman^{5,20}, Markus M Nöthen¹³⁵, Caroline Graff^{117,136}, Bruce M Psaty^{12,32,61,137}, Lesley

Jones⁶, Jonathan L Haines^{16,138}, Peter A Holmans⁶, Mark Lathrop^{21,22,139}, Margaret A Pericak-Vance^{13,14}, Lenore J Launer¹⁴⁰, Lindsay A Farrer^{9,10,11,141,142}, Cornelia M van Duijn^{5,20,143}, Christine Van Broeckhoven^{53,54}, Valentina Moskvina⁶, Sudha Seshadri^{142,145,146}, Julie Williams^{6,145,146}, Gerard D Schellenberg^{23,145,146}, and Philippe Amouyel^{1,2,3,28,144,145,146}

Affiliations

¹INSERM, U744, Lille, France. ²Université Lille 2, Lille, France. ³Institut Pasteur de Lille, Lille, France. ⁴Department of Neurology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. ⁵Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. ⁶Institute of Psychological Medicine and Clinical Neurosciences, Medical Research Council (MRC) Centre for Neuropsychiatric Genetics & Genomics, Cardiff University, Cardiff, UK. ⁷Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. ⁸Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. ⁹Department of Medicine (Biomedical Genetics), Boston University School of Public Health, Boston, Massachusetts, USA. ¹⁰Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, USA. ¹¹Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. ¹²Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA. ¹³John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA. ¹⁴Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida, USA. ¹⁵Functional Genomics Center Zurich, Eidgenössische Technische Hochschule (ETH)/University of Zurich, Zurich, Switzerland. ¹⁶Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, USA. ¹⁷Faculty of Medicine, University of Iceland, Reykjavik, Iceland. ¹⁸Icelandic Heart Association, Kopavogur, Iceland. ¹⁹Department of Radiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. ²⁰Netherlands Consortium for Healthy Aging, Leiden, The Netherlands. ²¹Centre National de Génotypage, Institut Génomique, Commissariat à l'Energie Atomique, Evry, France. ²²Fondation Jean Dausset, Centre d'Etude du Polymorphisme Humain (CEPH), Paris, France. ²³Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. ²⁴Institute for Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria. ²⁵Memory Clinic of Fundació Alzheimer Centre Educacional (ACE). Institut Català de Neurociències Aplicades, Barcelona, Spain. ²⁶Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, New York, USA. ²⁷Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, New York, USA. ²⁸Centre National de Référence pour les Malades Alzheimer Jeunes (CNR-MAJ), Centre Hospitalier Régional Universitaire de Lille, Lille, France. ²⁹Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany. ³⁰Institute of Human Genetics, University of Bonn, Bonn, Germany. ³¹University Paris Descartes, Sorbonne Paris V, Broca Hospital, Geriatrics Department, Paris, France. ³²Department of Epidemiology, University of Washington, Seattle, Washington, USA. ³³Department of Global Health, University of Washington, Seattle, Washington, USA. ³⁴Department of Neuroscience, Mount Sinai School of Medicine, New York, New York, USA. ³⁵Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA. ³⁶Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, USA. ³⁷CNR-MAJ, INSERM, U1079, Rouen University Hospital, Rouen,

France. ³⁸Department of Medicine, University of Washington, Seattle, Washington, USA. ³⁹German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. ⁴⁰Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany. ⁴¹Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA. ⁴²Hope Center Program on Protein Aggregation and Neurodegeneration, Washington University School of Medicine, St. Louis, Missouri, USA. ⁴³Ageing Group, Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, UK. ⁴⁴INSERM, U1061, Faculty of Medicine, Hôpital La Colombière, Montpellier, France. ⁴⁵Departments of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. ⁴⁶Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology & Psychiatry, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ⁴⁷Program in Medical and Population Genetics, Broad Institute, Boston, Massachusetts, USA. ⁴⁸Rush Institute for Healthy Aging, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA. ⁴⁹Institute of Psychiatry, King's College London, Denmark Hill, London, UK. ⁵⁰INSERM, U897, Victor Segalen University, Bordeaux, France. ⁵¹Departamento de Genómica Estructural, Neocodex, Seville, Spain. ⁵²Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK. ⁵³Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium. ⁵⁴Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. ⁵⁵Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA. ⁵⁶Mercer's Institute for Research on Aging, St. James Hospital and Trinity College, Dublin, Ireland. ⁵⁷Institute of Genetics, Queen's Medical Centre, University of Nottingham, Nottingham, UK. ⁵⁸Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁵⁹Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶⁰Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden. ⁶¹Group Health Research Institute, Group Health, Seattle, Washington, USA. ⁶²Department of Medicine and Partners Center for Personalized Genetic Medicine, Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ⁶³Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA. ⁶⁴University of Bristol Institute of Clinical Neurosciences, School of Clinical Sciences, Frenchay Hospital, Bristol, UK. ⁶⁵Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Ontario, Canada. ⁶⁶Institute of Primary Care and Public Health, Cardiff University, Neuadd Meirionnydd, University Hospital of Wales, Heath Park, Cardiff, UK. ⁶⁷Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. ⁶⁸Neurology Department. Biomedical Research Institute Sant Pau (IIB Sant Pau). Sant Pau Hospital. Universitat Autònoma de Barcelona, Barcelona, Spain. ⁶⁹Center for Networker Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona, Spain. ⁷⁰Geriatric Research, Education and Clinical Center (GRECC), Veteran Administration Puget Sound Health Care System (VAPSHCS), Seattle, Washington, USA. ⁷¹Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA. ⁷²Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece. ⁷³Clinical and Behavioral Neurology, Fondazione Santa Lucia, Rome, Italy. ⁷⁴MRC Prion Unit, Department of Neurodegenerative Disease, University College London Institute of Neurology, London, UK. ⁷⁵NEUROFARBA (Department of Neuroscience, Psychology, Drug

Research and Child Health), University of Florence, Florence, Italy. ⁷⁶Centro di Ricerca, Trasferimento e Alta Formazione DENOTHE, University of Florence, Florence, Italy. ⁷⁷Department of Immunology, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Spain. ⁷⁸Dementia Research Centre, Department of Neurodegenerative Disease, University College London Institute of Neurology, London, UK. ⁷⁹Department of Molecular Neuroscience, Institute of Neurology, London, UK. ⁸⁰Reta Lilla Weston Laboratories, Institute of Neurology, London, UK. ⁸¹Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Associazione Oasi Maria Santissima Srl, Troina, Italy. ⁸²Oxford Healthy Aging Project (OHAP), Clinical Trial Service Unit, University of Oxford, Oxford, UK. ⁸³Institute of Public Health, University of Cambridge, Cambridge, UK. ⁸⁴University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Milan, Italy. ⁸⁵Neurological Clinic, University of Pisa, Pisa, Italy. ⁸⁶MRC Biostatistics Unit, Cambridge, UK. ⁸⁸Urban Epidemiology, Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany. ⁸⁹Section of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy. ⁹⁰Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy. ⁹¹Department of Psychiatry, University of Frankfurt, Frankfurt am Main, Germany. ⁹²Department of Psychiatry, Ludwig Maximilians University, Munich, Germany. ⁹³Gerontology and Geriatrics Research Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy. ⁹⁴Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas–Universidad Autónoma de Madrid, Madrid, Spain. ⁹⁵Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. ⁹⁶Instituto de Investigación Sanitaria Hospital la Paz (IdIPaz), Madrid, Spain. ⁹⁷Departement of Geriatrics, Center for Aging Brain, University of Bari, Bari, Italy. ⁹⁸Department of Neuroscience, University of Parma, Parma, Italy. ⁹⁹Center for Cognitive Disorders, Azienda Unita Sanitaria Local (AUSL), Parma, Italy. ¹⁰⁰Department of Psychiatry, Saarland University Hospital, Homburg, Germany. ¹⁰¹Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden. ¹⁰²Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. ¹⁰³Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA. ¹⁰⁴National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, USA. ¹⁰⁵Genetica Molecular, Hospital Universitario Central Asturias, Oviedo, Spain. ¹⁰⁶Neurogenetics Laboratory, Division of Neurosciences, Center for Applied Medical Research, University of Navarra School of Medicine, Pamplona, Spain. ¹⁰⁷CIBERNED, Instituto de Salud Carlos III, Madrid, Spain. ¹⁰⁸Neurology Service, Marqués de Valdecilla University Hospital, University of Cantabria and Instituto de Formación e Investigación Marqués de Valdecilla (IFIMAV), Santander, Spain. ¹⁰⁹CIBERNED, Marqués de Valdecilla University Hospital, University of Cantabria and IFIMAV, Santander, Spain. ¹¹⁰Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana, USA. ¹¹¹Geriatric Department, Landspítali University Hospital, Reykjavik, Iceland. ¹¹²Institute of Clinical Medicine–Neurology, University of Eastern Finland, Kuopio, Finland. ¹¹³Department of Neurology, Kuopio University Hospital, Kuopio, Finland. ¹¹⁴Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. ¹¹⁵Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA. ¹¹⁶Department of Medicine (Geriatrics), University of Mississippi Medical Center, Jackson, Mississippi, USA. ¹¹⁷Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA. ¹¹⁸Department of Geriatric

Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden. ¹¹⁹Division of Clinical Neurosciences, School of Medicine, University of Southampton, Southampton, UK. ¹²⁰Department of Pathology, University of Washington, Seattle, Washington, USA. ¹²¹Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. ¹²²INSERM UMRS 975, CNRS UMR 7225, Université Pierre et Marie Curie, Centre de Recherche de l'Institut du Cerveau et de la Moëlle Epinière (CRICM), Hôpital de la Salpêtrière, Paris, France. ¹²³Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital de la Pitié-Salpêtrière, Paris, France. ¹²⁴Laboratory of Neurogenetics, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA. ¹²⁵Faculty of Medicine, Imperial College, St. Mary's Hospital, London, UK. ¹²⁶Department of Biology, Brigham Young University, Provo, Utah, USA. ¹²⁷Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA. ¹²⁸Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas, USA. ¹²⁹Division of Epidemiology, University of Texas Health Sciences Center at Houston, Houston, Texas, USA. ¹³⁰Hospital Universitari Vall d'Hebron-Institut de Recerca, Universitat Autònoma de Barcelona. (VHIR-UAB), Barcelona, Spain. ¹³¹Department of Neurology, Medical University of Graz, Graz, Austria. ¹³²Department of Psychiatry, University of Halle, Halle, Germany. ¹³³Centre de Mémoire de Ressources et de Recherche de Bordeaux, Centre Hospitalier Universitaire (CHU) de Bordeaux, Bordeaux, France. ¹³⁴INSERM, U708, Victor Segalen University, Bordeaux, France. ¹³⁵Institute of Human Genetics, Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany. ¹³⁶Department of Neurobiology, Karolinska Institutet, Care Sciences and Society, Karolinska Institute-Alzheimer's Disease Research Center (KIADRC), Stockholm, Sweden. ¹³⁷Department of Health Service, University of Washington, Seattle, Washington, USA. ¹³⁸Vanderbilt Center for Human Genetics Research, Vanderbilt University, Nashville, Tennessee, USA. ¹³⁹McGill University and Génome Québec Innovation Centre, Montreal, Quebec, Canada. ¹⁴⁰Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, Maryland, USA. ¹⁴¹Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA. ¹⁴²Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA. ¹⁴³Center for Medical Systems Biology, Leiden, The Netherlands. ¹⁴⁴Centre Hospitalier Régional Universitaire de Lille, Lille, France.

Acknowledgments

This work was made possible by the generous participation of the control subjects, the patients and their families. iSelect chips were funded by the French National Foundation on Alzheimer's Disease and Related Disorders. Data management involved the Centre National de Génotypage and was supported by the Institut Pasteur de Lille, INSERM, FRC (Fondation pour la Recherche sur le Cerveau) and Rotary. This work has been developed and supported by the LABEX (Laboratory of Excellence Program Investment for the Future) DISTALZ grant (Development of Innovative Strategies for a Transdisciplinary Approach to Alzheimer's Disease). The French National Foundation on Alzheimer's Disease and Related Disorders and the Alzheimer's Association (Chicago, Illinois) grant supported in-person meetings and communication for IGAP, and the Alzheimer's Association (Chicago, Illinois) grant provided some funds to each consortium for analyses.

GERAD was supported by the Wellcome Trust, the MRC, Alzheimer's Research UK (ARUK) and the Welsh government. ADGC and CHARGE were supported by the US National Institutes of Health, National Institute on Aging (NIH-NIA), including grants U01 AG032984 and R01 AG033193 (additional US National Institutes of Health grant numbers are listed in the Supplementary Note). CHARGE was also supported by Erasmus Medical Center and Erasmus University.

Complete acknowledgments are detailed in the Supplementary Note.

References

1. Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*. 1993; 261:921–923. [PubMed: 8346443]
2. Genin E, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. *Mol. Psychiatry*. 2011; 16:903–907.
3. Lambert J-C, et al. Genome-wide association study identifies variants at *CLU* and *CR1* associated with Alzheimer's disease. *Nat. Genet.* 2009; 41:1094–1099. [PubMed: 19734903]
4. Harold D, et al. Genome-wide association study identifies variants at *CLU* and *PICALM* associated with Alzheimer's disease. *Nat. Genet.* 2009; 41:1088–1093. [PubMed: 19734902]
5. Seshadri S, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. *J. Am. Med. Assoc.* 2010; 303:1832–1840.
6. Hollingworth P, et al. Common variants at *ABCA7 MS4A6A/MS4A4E EPHA1 CD33* and *CD2AP* are associated with Alzheimer's disease. *Nat. Genet.* 2011; 43:429–435.
7. Naj AC, et al. Common variants at *MS4A4/MS4A6E CD2AP CD33* and *EPHA1* are associated with late-onset Alzheimer's disease. *NatGenet.* 2011; 43:436–441.
8. Guerreiro R, et al. *TREM2* variants in Alzheimer's disease. *N. Engl. J. Med.* 2013; 368:117–127.
9. Jonsson T, et al. Variant of *TREM2* associated with the risk of Alzheimer's disease. *N. Engl. J. Med.* 2013; 368:107–116.
10. Miyashita A, et al. *SORL1* is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. *PLoS ONE*. 2013; 8:e58618.
11. Cruchaga C, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. *Neuron*. 2013; 78:256–268. [PubMed: 23562540]
12. Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. *Nature*. 2011; 476:214–219.
13. Nalls MA, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet*. 2011; 377:641–649. [PubMed: 21292315]
14. Rogava E, et al. The neuronal sortilin-related receptor *SORL1* is genetically associated with Alzheimer disease. *Nat. Genet.* 2007; 39:168–177. [PubMed: 17220890]
15. Pottier C, et al. High frequency of potentially pathogenic *SORL1* mutations in autosomal dominant early-onset Alzheimer disease. *Mol. Psychiatry*. 2012; 17:875–879. [PubMed: 22472873]
16. Pandey P, et al. Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism. *J. Biol. Chem.* 1999; 274:10140–10144. [PubMed: 10187797]
17. Huang Y, et al. CAK β /Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. *Neuron*. 2001; 29:485–496. [PubMed: 11239437]
18. Williamson R, et al. CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases. *J. Alzheimers Dis.* 2011; 27:615–625.
19. Sulem P, et al. Genetic determinants of hair, eye and skin pigmentation in Europeans. *Nat. Genet.* 2007; 39:1443–1452. [PubMed: 17952075]
20. Adeyemo A, et al. A genome-wide association study of hypertension and blood pressure in African Americans. 2009; 5:e1000564.
21. Larsson M, et al. GWAS findings for human iris patterns: associations with variants in genes that influence normal neuronal pattern development. *Am. J. Hum. Genet.* 2011; 89:334–343.
22. Kajiho H, et al. RIN3: a novel Rab5 GEF interacting with amphiphysin II involved in the early endocytic pathway. *J. Cell Sci.* 2003; 116:4159–4168.
23. Chapuis J, et al. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. *Mol. Psychiatry*. Feb 12.2013
24. He F, et al. Structural insight into the zinc finger CW domain as a histone modification reader. *Structure*. 2010; 18:1127–1139.

25. Yokoyama K, et al. NYAP: a phosphoprotein family that links PI3K to WAVE1 signalling in neurons. *EMBO J.* 2011; 30:4739–4754. [PubMed: 21946561]
26. Gallo JM, Spickett C. The role of CELF proteins in neurological disorders. *RNA Biol.* 2010; 7:474–479. [PubMed: 20622515]
27. Del Villar K, Miller CA. Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons. *Proc. Natl. Acad. Sci. USA.* 2004; 101:4210–4215. [PubMed: 15007167]
28. Duriez B, et al. A common variant in combination with a nonsense mutation in a member of the thioredoxin family causes primary ciliary dyskinesia. *Proc. Natl. Acad. Sci. USA.* 2007; 104:3336–3341. [PubMed: 17360648]
29. Pluskota E, et al. The integrin coactivator kindlin-2 plays a critical role in angiogenesis in mice and zebrafish. *Blood.* 2011; 117:4978–4987. [PubMed: 21378273]
30. Shulman JM, et al. Functional screening in *Drosophila* identifies Alzheimer's disease susceptibility genes and implicates Tau-mediated mechanisms. *Hum. Mol. Genet.* Oct 9.2013
31. Kirsch KH, Georgescu MM, Ishimaru S, Hanafusa H. CMS: an adapter molecule involved in cytoskeletal rearrangements. *Proc. Natl. Acad. Sci. USA.* 1999; 96:6211–6216. [PubMed: 10339567]
32. Bao M, et al. CD2AP/SHIP1 complex positively regulates plasmacytoid dendritic cell receptor signaling by inhibiting the E3 ubiquitin ligase Cbl. *J. Immunol.* 2012; 189:786–792. [PubMed: 22706086]
33. Brauer H, et al. Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling. *Cell. Signal.* 2012; 24:2095–2101.
34. Le Meur N, et al. MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations. *J. Med. Genet.* 2010; 47:22–29. [PubMed: 19592390]
35. Akhtar MW, et al. In vivo analysis of MEF2 transcription factors in synapse regulation and neuronal survival. *PLoS ONE.* 2012; 7:e34863. [PubMed: 22496871]
36. Griciuc A, et al. Alzheimer's disease risk gene *CD33* inhibits microglial uptake of amyloid β . *Neuron.* 2013; 78:631–643.
37. Lambert JC, Amouyel P. Genetics of Alzheimer's disease: new evidences for an old hypothesis? *Curr. Opin. Genet. Dev.* 2011; 21:295–301. [PubMed: 21371880]
38. Lambert J-C, et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. *J. Alzheimers Dis.* 2010; 20:1107–1118. [PubMed: 20413860]
39. Jones L, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PLoS ONE.* 2010; 5:e13950. [PubMed: 21085570]
40. Brouwers N, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. *Mol. Psychiatry.* 2012; 17:223–233. [PubMed: 21403675]
41. Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. *Lancet Neurol.* 2013; 12:92–104. [PubMed: 23237904]
42. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* 2009; 5:e1000529. [PubMed: 19543373]
43. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet. Epidemiol.* 2010; 34:816–834. [PubMed: 21058334]
44. Purcell S, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. *Am. J. Hum. Genet.* 2007; 81:559–575. [PubMed: 17701901]
45. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies via imputation of genotypes. *Nat. Genet.* 2007; 39:906–913. [PubMed: 17572673]
46. Aulchenko YS, Struchalin MV, van Duijn CM. ProbABEL package for genome-wide association analysis of imputed data. *BMC Bioinformatics.* 2010; 11:134.

47. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. *PLoS Genet.* 2006; 2:e190. [PubMed: 17194218]
48. Bellenguez C, et al. A robust clustering algorithm for identifying problematic samples in genome-wide association studies. *Bioinformatics.* 2012; 28:134–135.
49. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics.* 2010; 26:2190–2191. [PubMed: 20616382]
50. Mägi R, Morris AP. GWAMA: software for genome-wide association meta-analysis. *BMC Bioinformatics.* 2010; 11:288.
51. Pruim RJ, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics.* 2010; 26:2336–2337. [PubMed: 20634204]
52. Levin ML. The occurrence of lung cancer in man. *Acta Unio Int. Contra Cancrum.* 1953; 9:531–541. [PubMed: 13124110]




Figure 1.

Manhattan plot of stage 1 for genome-wide association with Alzheimer's disease (17,008 cases and 37,154 controls). The threshold for genome-wide significance ($P < 5 \times 10^{-8}$) is indicated by the red line. Genes previously identified by GWAS are shown in black, and newly associated genes are shown in red. Red diamonds represent SNPs with the smallest P values in the overall analysis.




Figure 2.
Regional plot for the *PTK2B-CLU* locus (17,008 cases and 37,154 controls).

Table 1

Description of the consortium data sets used for stage 1 and stage 2

Consortium	Alzheimer's disease cases				Controls			
	<i>N</i>	Percent women	Mean AAO (s.d.)		<i>N</i>	Percent women	Mean AAE (s.d.)	
ADGC	10,273	59.4	74.7 (7.7)		10,892	58.6	76.3 (8.1)	
CHARGE	1,315	63.6	82.7 (6.8)		12,968	57.8	72.8 (8.6)	
Stage 1 EADI	2,243	64.9	68.5 (8.9)		6,017	60.7	74.0 (5.4)	
GERAD	3,177	64.0	73.0 (8.5)		7,277	51.8	51.0 (11.8)	
<i>N</i>	17,008				37,154			
Country	<i>N</i>	Percent women	Mean AAO (s.d.)		<i>N</i>	Percent women	Mean AAE (s.d.)	
Austria	210	61.0	72.5 (8.1)		829	43.3	65.5 (8.0)	
Belgium	878	66.1	75.4 (8.6)		661	59.5	65.7 (14.3)	
Finland	422	68.0	71.4 (6.9)		562	59.3	69.1 (6.2)	
Germany	972	63.9	73.0 (8.6)		2,378	53.1	69.5 (10.1)	
Greece	256	63.3	69.2 (8.0)		229	34.1	49.3 (16.4)	
Stage 2 Hungary	125	68.0	74.9 (6.8)		100	69.0	74.4 (6.5)	
Italy	1,729	66.5	71.5 (8.7)		720	55.7	70.0 (10.4)	
Spain	2,121	66.3	75.0 (8.3)		1,921	55.3	70.2 (10.8)	
Sweden	797	61.7	76.8 (8.1)		1,506	62.8	70.6 (8.7)	
UK	490	57.6	74.6 (8.7)		1,066	29.2	73.8 (6.5)	
United States	572	61.9	83.5 (7.6)		1,340	54.0	79.3 (6.8)	
<i>N</i>	8,572				11,312			

AAO, age at onset; AAE, age at examination.

Table 2

summary of stage 1, stage 2 and overall meta-analyses for sNPs reaching genome-wide significance after stages 1 and 2

SNP ^a	Chr.	Position ^b	Closest gene ^c	Major/minor alleles	MAF ^d	Stage 1			Stage 2			Overall		
						OR (95% CI) ^e	Meta P value	OR (95% CI) ^e	Meta P value	OR (95% CI) ^e	Meta P value	I ² (%) ^f	P value ^f	
Known GWAS-defined associated genes														
rs6656401	1	207692049	<i>CRI</i>	G/A	0.197	1.17 (1.12–1.22)	7.7×10^{-15}	1.21 (1.14–1.28)	7.9×10^{-11}	1.18 (1.14–1.22)	5.7×10^{-24}	0, 7.8×10^{-1}		
rs6733839	2	127892810	<i>BINI</i>	C/T	0.409	1.21 (1.17–1.25)	1.7×10^{-26}	1.24 (1.18–1.29)	3.4×10^{-19}	1.22 (1.18–1.25)	6.9×10^{-44}	28, 6.1×10^{-2}		
rs10948363	6	47487762	<i>CD2AP</i>	A/G	0.266	1.10 (1.07–1.14)	3.1×10^{-8}	1.09 (1.04–1.15)	4.1×10^{-4}	1.10 (1.07–1.13)	5.2×10^{-11}	0, 9×10^{-1}		
rs11771145	7	143110762	<i>EPHA1</i>	G/A	0.338	0.90 (0.87–0.93)	8.8×10^{-10}	0.90 (0.86–0.95)	2.8×10^{-5}	0.90 (0.88–0.93)	1.1×10^{-13}	14, 2.4×10^{-1}		
rs9331896	8	27467686	<i>CLU</i>	T/C	0.379	0.86 (0.84–0.89)	9.6×10^{-17}	0.86 (0.82–0.90)	4.5×10^{-10}	0.86 (0.84–0.89)	2.8×10^{-25}	0, 4.9×10^{-1}		
rs983392	11	59923508	<i>MSHA6A</i>	A/G	0.403	0.90 (0.87–0.93)	2.8×10^{-11}	0.90 (0.86–0.94)	4.5×10^{-6}	0.90 (0.87–0.92)	6.1×10^{-16}	1, 4.5×10^{-1}		
rs10792832	11	85867875	<i>PICALM</i>	G/A	0.358	0.88 (0.85–0.91)	6.5×10^{-16}	0.85 (0.81–0.89)	1.1×10^{-11}	0.87 (0.85–0.89)	9.3×10^{-26}	0, 9.8×10^{-1}		
rs4147929	19	1063443	<i>ABCA7</i>	G/A	0.190	1.14 (1.10–1.20)	1.7×10^{-9}	1.17 (1.10–1.24)	9.9×10^{-8}	1.15 (1.11–1.19)	1.1×10^{-15}	0, 9.4×10^{-1}		
rs38654448	19	51727962	<i>CD33</i>	C/A	0.307	0.91 (0.88–0.94)	5.1×10^{-8}	0.99 (0.94–1.04)	6.9×10^{-1}	0.94 (0.91–0.96)	3.0×10^{-6}	0, 6.9×10^{-1}		
New loci reaching genome-wide significance in the discovery analysis														
rs9271192	6	32578530	<i>HLA-DRB5–HLA-DRB1</i>	A/C	0.276	1.11 (1.07–1.16)	1.6×10^{-8}	1.12 (1.06–1.18)	4.2×10^{-5}	1.11 (1.08–1.15)	2.9×10^{-12}	0, 5.4×10^{-1}		
rs28834970	8	27195121	<i>PTK2B</i>	T/C	0.366	1.10 (1.07–1.14)	3.3×10^{-9}	1.11 (1.06–1.17)	4.3×10^{-6}	1.10 (1.08–1.13)	7.4×10^{-14}	10, 3.0×10^{-1}		
rs11218343	11	121435587	<i>SORL1</i>	T/C	0.039	0.76 (0.70–0.83)	5.0×10^{-11}	0.78 (0.70–0.88)	4.0×10^{-5}	0.77 (0.72–0.82)	9.7×10^{-15}	0, 8.3×10^{-1}		
rs10498633	14	92926952	<i>SLC24A4 RIN3</i>	G/T	0.217	0.90 (0.87–0.94)	1.5×10^{-7}	0.93 (0.88–0.98)	7.8×10^{-3}	0.91 (0.88–0.94)	5.5×10^{-9}	0, 6.3×10^{-1}		
rs80937318	18	29088958	<i>DSG2</i>	C/T	0.017	0.54 (0.43–0.67)	4.6×10^{-8}	1.01 (0.80–1.28)	9.0×10^{-1}	0.73 (0.62–0.86)	1.0×10^{-4}	38, 3.9×10^{-2}		
New loci reaching genome-wide significance in the combined discovery and replication analysis														
rs35349669	2	234068476	<i>INPP5D</i>	C/T	0.488	1.07 (1.03–1.10)	9.6×10^{-5}	1.10 (1.05–1.15)	5.7×10^{-5}	1.08 (1.05–1.11)	3.2×10^{-8}	0, 8.0×10^{-1}		

SNP ^a	Chr.	Position ^b	Closest gene ^c	Major/minor alleles	MAF ^d	Stage 1			Stage 2			Overall		
						OR (95% CI) ^e	Meta P value	OR (95% CI) ^e	Meta P value	OR (95% CI) ^e	Meta P value	I ² (%), P value ^f		
rs190982	5	882223420	<i>MEF2C</i>	A/G	0.408	0.92 (0.89–0.95)	2.5 × 10 ⁻⁶	0.93 (0.89–0.98)	3.4 × 10 ⁻³	0.93 (0.90–0.95)	3.2 × 10 ⁻⁸	0, 6.4 × 10 ⁻¹		
rs2718058	7	37841534	<i>NME8</i>	A/G	0.373	0.93 (0.90–0.96)	1.3 × 10 ⁻⁵	0.91 (0.87–0.95)	6.3 × 10 ⁻⁵	0.93 (0.90–0.95)	4.8 × 10 ⁻⁹	0, 9.2 × 10 ⁻¹		
rs1476679	7	100004446	<i>ZCWPW1</i>	T/C	0.287	0.92 (0.89–0.96)	7.4 × 10 ⁻⁶	0.89 (0.85–0.94)	9.7 × 10 ⁻⁶	0.91 (0.89–0.94)	5.6 × 10 ⁻¹⁰	0, 7.0 × 10 ⁻¹		
rs10838725	11	47557871	<i>CELF1</i>	T/C	0.316	1.08 (1.04–1.11)	6.7 × 10 ⁻⁶	1.09 (1.04–1.14)	4.1 × 10 ⁻⁴	1.08 (1.05–1.11)	1.1 × 10 ⁻⁸	0, 7.6 × 10 ⁻¹		
rs17125944	14	53400629	<i>FERMT2</i>	T/C	0.092	1.13 (1.07–1.19)	1.0 × 10 ⁻⁵	1.17 (1.08–1.26)	1.6 × 10 ⁻⁴	1.14 (1.09–1.19)	7.9 × 10 ⁻⁹	10, 3.0 × 10 ⁻¹		
rs7274581	20	55018260	<i>CASS4</i>	T/C	0.083	0.87 (0.82–0.92)	1.6 × 10 ⁻⁶	0.89 (0.82–0.96)	4.1 × 10 ⁻³	0.88 (0.84–0.92)	2.5 × 10 ⁻⁸	0, 9.9 × 10 ⁻¹		

Chr., chromosome.

^aSNPs showing the best level of association after meta-analysis of stages 1 and 2.

^bBuild 37, assembly hg19.

^cGenes located ± 100 kb of the top SNP.

^dAverage in the discovery sample.

^eCalculated with respect to the minor allele.

^fCochran's *Q* test.

^gNot replicated in stage 2.